Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Mark Bong who wrote (1047)	10/22/2001 4:11:36 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 1475

I believe Macrogenics is in part founded by Ruedi A and Lee H and has taken down some lab space in or near the ISB. From Puget Sound Business Journal: Biotech MacroGenics ramps up with funding, CEO MacroGenics Inc., a fledgling biotech spinoff of the Seattle-based Institute for Systems Biology, has raised $13.5 million and hired a president and chief executive officer. MacroGenics, which is developing immunotherapeutics for the treatment of cancer and inflammatory diseases, said it is developing a research site in Seattle to allow it to collaborate with scientists at the Institute for Systems Biology. Founded in August 2000, Rockville, Md.-based MacroGenics is backed financially by venture firms InterWest Partners, MPM Capital, and OrbiMed. The company hired Scott Koenig to take over day-to-day operations. Koenig has been at MedImmune Inc. for the past 11 years, most recently as senior vice president, where he led research discovery efforts, including the identification of candidate monoclonal antibodies and vaccines for the prevention and treatment of viral and bacterial infections, cancer, autoimmune diseases, and complications of transplantation. The nonprofit Institute for Systems Biology, founded by biotechnology pioneer LeRoy Hood, signed a lease earlier this year for its new headquarters facility near Seattle's Gasworks Park to accommodate the growth expected from additional partnership efforts with academia and industry. The institute, which seeks to advance the research of the Human Genome Project, plans to move its 150 staff members there by late fall, depending on when the lab and office space inside the building is ready. The institute was created to allow researchers from different disciplines -- ranging from astrophysics to protein chemistry -- to work together to advance biological research and education. It also makes partnerships between researchers and private industry easier, by freeing them from the regulations and bureaucracy imposed on state-run academic institutions. Wilder